Participated · Series B · Jul 2026

Sereact builds AI software models that give robots general-purpose visual perception and manipulation abilities, and it ships those models to run on a wide range of robot hardware. The company launched Cortex 2, an AI model that trains robots on different physical behaviors so they can select the action most likely to succeed. Sereact says it does not build robots or sell services, positioning its shipped model as the product that runs on single-arm, dual-arm, humanoid and fixed-cell robots. Its technology is deployed with customers including BMW, Daimler Truck, Bol and Active Ants, and real-world deployments generate a data flywheel that improves system performance. The company was founded in 2021, is based in Stuttgart, employs about 100 people, and is using new funding to further develop Cortex 2 and expand into the U.S., including a Boston office.

Participated · Series A · Jun 2026

Founded in 2021, Astral Systems designs and operates compact multi-state fusion (MSF) reactors to generate high-intensity neutron beams for manufacturing medical isotopes. The company currently operates reactors at TRL9, runs three commercial fusion facilities, and has signed research contracts that have generated more than £3M in revenue. Astral has partnered with McMaster University and Brazil’s Institute for Energy and Nuclear Research to produce isotopes including Actinium-225 and Lead-212, and plans to bring at least one isotope to market by early 2027. With the Series A financing, Astral intends to build out next-generation reactors at the former Berkeley Power Station, expand its headcount from 23 to more than 40 by end-2026, and target profitability in 2027. The firm positions its modular MSF design as able to produce a broader range of isotopes than single-purpose competitors.

Led · Equity · Jun 2026

Graph Therapeutics develops precision therapeutics for inflammatory and immune-mediated diseases by combining perturbation modelling of complex live patient samples, functional and multi-omics profiling, and advanced machine learning in a proprietary "lab-in-the-loop" AI platform. The company uses insights derived directly from patient tissue to identify disease mechanisms, novel therapeutic targets, and biomarkers to inform differentiated therapy development. Graph has validated and de-risked its platform with clinically relevant biological models and is advancing an internal pipeline of precision drug candidates across multiple indications. The maturity of the platform also creates opportunities for strategic partnerships and out-licensing to extend the technology beyond its internal programs. Financially, Graph has raised more than $10 million to date, comprising equity investments and non-dilutive grant funding.

Participated · Series A · Jun 2026

Rocapine develops a portfolio of wellness apps that aim to support healthier daily habits by prioritising wellbeing rather than maximizing engagement. Founded in late 2024 by Stanislas Marchand (CEO), Jean-Gabriel Boinot-Tramoni and Sammy Teillet, the company has launched apps across women's health, addiction therapy and nutrition, including Harmony, That Girl and Unchaind. The studio describes its products as designed to "hold instead of hook" and uses AI-driven tools and a testing engine to iterate on app ideas. Rocapine plans to scale its testing engine to 400 apps this year and invest in AI, data and marketing infrastructure to grow category leaders. Its recent $13M Series A provides the capital to execute on these expansion plans.

Participated · Series A · May 2026

Founded in 2019, VorteX-io develops and deploys hydrological monitoring solutions at scale. The company employs about 30 people and reported collecting four million data points last year. It has deployed nearly 1,000 monitoring stations across four continents. VorteX-io positions its offering to serve states, government agencies and large international organizations concerned with sovereign water resource management. The company emphasizes data mastery, infrastructure control and decision-making capabilities as central to managing water sovereignty. It was a laureate in the "Transition écologique" category at the Masters Occitanie Ouest 2025.